Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) shares traded down 9.6% on Tuesday . The stock traded as low as $16.85 and last traded at $16.85. 91,226 shares changed hands during mid-day trading, a decline of 58% from the average session volume of 215,827 shares. The stock had previously closed at $18.64.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised Pulse Biosciences to a "sell" rating in a research report on Tuesday, August 6th.
Get Our Latest Research Report on Pulse Biosciences
Pulse Biosciences Stock Down 8.3 %
The stock has a market capitalization of $944.35 million, a P/E ratio of -21.11 and a beta of 1.75. The firm has a 50-day moving average of $16.27 and a 200 day moving average of $11.86.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Pulse Biosciences by 28.8% in the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company's stock worth $7,379,000 after purchasing an additional 189,227 shares during the period. Cetera Advisors LLC bought a new position in shares of Pulse Biosciences during the first quarter valued at $109,000. BNP Paribas Financial Markets lifted its holdings in shares of Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company's stock valued at $66,000 after acquiring an additional 2,952 shares during the period. PNC Financial Services Group Inc. bought a new position in shares of Pulse Biosciences during the fourth quarter valued at $242,000. Finally, Price T Rowe Associates Inc. MD bought a new position in shares of Pulse Biosciences during the first quarter valued at $88,000. 76.95% of the stock is owned by institutional investors.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Further Reading
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
